Skip to main content

Table 1 Clinicopathological factors of triple-negative breast tumors with the status of CD8, FOXP3, the ratio of CD8/FOXP3 (N=101)

From: Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study

Factors CD8 FOXP3 CD8/FOXP3
High Low P value High Low P value High Low P value
Age, years    0.838    0.415    0.682
 <50 22 17   22 17   16 23  
 >50 33 29   29 33   29 33  
Residual tumor size    0.005*    0.373    0.487
 <2.0 cm 39 20   32 27   28 31  
 >2.0 cm 16 26   19 23   17 25  
Nodal status after NAC    0.167    0.491    0.094
 Negative 35 23   31 27   30 28  
 Positive 20 23   20 23   15 28  
Residual cancer burden    0.052    0.908    0.013*
 Class I 5 2   3 4   6 1  
 Class II 41 27   35 33   32 36  
 Class III 9 17   13 13   7 19  
Histological grade    0.602    0.329    0.068
 I, II 21 16   15 22   22 17  
 III 34 30   36 28   23 39  
Neoadjuvant chemotherapy    0.726    0.319    0.136
 Anthracycline and taxane-based 45 40   43 42   39 46  
 Anthracycline-based 9 5   8 6   4 10  
 Other 1 1   0 2   2 0  
Basal-like type    0.314    0.546    0.417
 Basal-like 30 30   32 28   29 31  
 Non basal-like 25 16   19 22   16 25  
Ki-67 LI (cutoff: 50)    0.551    0.322    0.056
 Low 26 25   23 28   28 23  
 High 29 21   28 22   17 33  
CD8 (cutoff: 100)       0.0003*    0.010*
 Low     14 32   14 32  
 High     37 18   31 24  
FOXP3 (cutoff: 60)    0.0003*       0.0001*
 Low 18 32      32 18  
 High 37 14      13 38  
CD8/FOXP3 (cutoff: 1.6)    0.010*    0.0001*    
 Low 24 32   38 18     
 High 31 14   13 32     
  1. NAC neoadjuvant chemotherapy, LI labeling index
  2. *The P value is significant